Patients denied Alzeimer's drugs on NHS

Shocking plans to restrict the use of patients using Alzeimer's drugs on the NHS will be challenged in court by two drugs companies it emerged last week. Eisai and Pfizer will seek a judicial review of a decsion by The National Institute for Health and Clinical Excellence (NICE) to deny patients using Aricept, Exelon and Reminyl on the NHS. Rebecca Wood, Chief Executive of The Alzeimer's Research Trust, said: 'NICE'S wrong headed decision has been an apalling insult to the thousands of families up and down the country who have been blighted by Alzeimer's.' The drugs cost  £2.50 per day and the Chief Executive claims that they are effective and 'offer good value for money.' She agreed that more research into new medicines was needed but said that if NICE continue with the ruling, it will 'exascerbate the time-ticking bomb of an ageing Britain.' NICE's ruling is expected to come into force on the 22nd November as new patients will be unable to access these drugs on the NHS.